Insmed (NSM) Doses First Patient in ARIKACE Phase 2

June 27, 2012 8:02 AM EDT Send to a Friend
Insmed Incorporated (Nasdaq: INSM), announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACEĀ® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial).


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment